Merger uncertainty and impending trials for Bristol-Myers leave investors in limbo By: MarketWatch June 05, 2019 at 12:09 PM EDT Investors are taking a wait-and-see approach to Bristol-Myers Squibb Co., according to Credit Suisse. Read More >> Related Stocks: Bristol-Myers Squibb Celgene Corp
